ID: ALA2087454

Max Phase: Preclinical

Molecular Formula: C19H25N5O3

Molecular Weight: 371.44

Molecule Type: Small molecule

Representations

Canonical SMILES:  COc1ccc(-c2cc(NC(=O)CCCCN3CCNC(=O)C3)[nH]n2)cc1

Standard InChI:  InChI=1S/C19H25N5O3/c1-27-15-7-5-14(6-8-15)16-12-17(23-22-16)21-18(25)4-2-3-10-24-11-9-20-19(26)13-24/h5-8,12H,2-4,9-11,13H2,1H3,(H,20,26)(H2,21,22,23,25)

Standard InChI Key:  XJQFQLWVHXSRMJ-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 371.44

Molecular Weight (Monoisotopic): 371.1957

AlogP: 1.63

#Rotatable Bonds: 8

Polar Surface Area: 99.35

Molecular Species: NEUTRAL

HBA: 5

HBD: 3

#RO5 Violations: 0

HBA (Lipinski): 8

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 11.18

CX Basic pKa: 6.44

CX LogP: 1.06

CX LogD: 1.02

Aromatic Rings: 2

Heavy Atoms: 27

QED Weighted: 0.61

Np Likeness Score: -1.59

References

1. Zanaletti R, Bettinetti L, Castaldo C, Cocconcelli G, Comery T, Dunlop J, Gaviraghi G, Ghiron C, Haydar SN, Jow F, Maccari L, Micco I, Nencini A, Scali C, Turlizzi E, Valacchi M..  (2012)  Discovery of a novel alpha-7 nicotinic acetylcholine receptor agonist series and characterization of the potent, selective, and orally efficacious agonist 5-(4-acetyl[1,4]diazepan-1-yl)pentanoic acid [5-(4-methoxyphenyl)-1H-pyrazol-3-yl] amide (SEN15924, WAY-361789).,  55  (10): [PMID:22468936] [10.1021/jm300247y]

Source

Source(1):

• Scientific Literature